Bank of Montreal Can Buys 29,230 Shares of RxSight, Inc. (NASDAQ:RXST)

Bank of Montreal Can increased its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 32.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 119,580 shares of the company's stock after buying an additional 29,230 shares during the quarter. Bank of Montreal Can owned 0.30% of RxSight worth $5,804,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. CWM LLC increased its position in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after acquiring an additional 371 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock worth $29,000 after purchasing an additional 521 shares during the period. Quest Partners LLC bought a new position in RxSight during the 2nd quarter worth about $41,000. KBC Group NV raised its stake in shares of RxSight by 63.6% in the 3rd quarter. KBC Group NV now owns 1,232 shares of the company's stock valued at $61,000 after purchasing an additional 479 shares during the period. Finally, Amalgamated Bank lifted its holdings in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors.

RxSight Price Performance

NASDAQ:RXST traded down $1.92 during trading hours on Tuesday, hitting $43.92. The company's stock had a trading volume of 143,002 shares, compared to its average volume of 485,435. The company has a market capitalization of $1.77 billion, a P/E ratio of -53.75 and a beta of 1.11. RxSight, Inc. has a twelve month low of $29.97 and a twelve month high of $66.54. The stock has a fifty day simple moving average of $48.58 and a 200-day simple moving average of $52.17.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price objective on the stock. Wells Fargo & Company reduced their price objective on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Stifel Nicolaus lowered their target price on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Finally, Oppenheimer lowered their price target on RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight presently has a consensus rating of "Buy" and a consensus target price of $61.63.

Insider Activity at RxSight

In other news, insider Ilya Goldshleger sold 1,330 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $46.13, for a total transaction of $61,352.90. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at $1,948,807.98. This trade represents a 3.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jesse Anderson Corley acquired 11,111 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The stock was bought at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the purchase, the director now owns 468,571 shares of the company's stock, valued at $21,259,066.27. This trade represents a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 62,702 shares of company stock valued at $3,059,197 in the last 90 days. 9.36% of the stock is owned by corporate insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.